Esperite N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 mrt 2015 - 07:28
Statutaire naam
Esperite N.V.
Titel
ESPERITE (ESP) financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015
Bericht
ESPERITE ("Esperite N.V. (Euronext: ESP, "ESPERITE" or "the Company") strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests
Stem cell historical CryoSave's core business now profitable and improving
Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results
Zutphen, The Netherlands - 17 March 2015
Frederic Amar, appointed ESPERITE CEO on March 2014, is implementing from the onset an aggressive reorganization and development of the company. Frederic Amar's far-reaching new business model has materialized in three separate synergetic business units attacking new markets with a diversified offer, transforming a mono-product business model into a biotech multiservice company. ESPERITE's consolidated operations feature now reduced complexity, sustainable lower overhead, centralized administrative services, integrated sales and marketing strategies coupled with the technology to handle large volumes efficiently. The preliminary (unaudited) financial results for year ended 31 December 2014 published today reflect these improvements.
Gerelateerde downloads
Datum laatste update: 27 juli 2024